Vagifem Shortage: What Providers and Prescribers Need to Know in 2026

This resource is intended for healthcare providers — OB/GYNs, primary care physicians, nurse practitioners, and menopause specialists — who prescribe Vagifem (estradiol vaginal inserts, 10 mcg) for patients with genitourinary syndrome of menopause (GSM). It summarizes the current availability situation in 2026, provides a clinical framework for managing patients who cannot fill their prescription, and identifies appropriate therapeutic alternatives.

Current Shortage Status (2026)

Vagifem is not currently listed on the FDA Drug Shortages Database or the ASHP Drug Shortage Bulletin. Novo Nordisk continues to manufacture Vagifem at its facility in Bagsvaerd, Denmark, and it remains commercially available through U.S. pharmaceutical distribution networks.

However, individual pharmacy-level stock-outs are commonly reported by patients. This is driven by a combination of factors: increased prescribing driven by growing awareness of GSM, the relatively low stocking volumes typical of specialty vaginal hormone products, and the international manufacturing origin of Vagifem (Denmark). A prescriber receiving calls from patients who cannot fill their Vagifem prescription is not necessarily encountering a shortage — it may be a distribution or stocking issue resolvable with pharmacy-level intervention.

The related product Estring (estradiol vaginal system, Pfizer) was placed on the ASHP shortage list in 2024 due to manufacturing delays. Prescribers should verify current Estring availability if they plan to switch patients to the ring formulation.

Clinical Considerations for GSM Management During Availability Gaps

Genitourinary syndrome of menopause is a chronic, progressive condition. Interruption of vaginal estrogen therapy, even brief, can result in symptom recurrence and regression of epithelial tissue improvements. Clinical guidance from The Menopause Society (formerly NAMS) endorses ongoing treatment as appropriate and emphasizes that localized vaginal estrogen is safe even in many patients with histories that preclude systemic HRT.

When patients experience a medication gap due to stock unavailability, the clinical priority is to bridge therapy as quickly as possible — ideally within 7-14 days — before significant regression occurs.

Therapeutically Equivalent and Alternative Options

Tier 1 — Direct Substitution (Same molecule, same dose):

• Generic estradiol vaginal inserts 10 mcg (Teva, Glenmark, others): FDA-approved, bioequivalent to Vagifem. Same dose, same schedule. If writing brand-only, revise to allow DAW-0 substitution.
• Yuvafem (Amneal): Branded generic of Vagifem. Estradiol 10 mcg vaginal insert. Bioequivalent.

Tier 2 — Same molecule, different delivery system:

• Imvexxy (estradiol 4 mcg or 10 mcg, TherapeuticsMD): Soft gel insert, finger-inserted. FDA-approved for moderate-to-severe dyspareunia. Brand-only. Maintenance dosing is the same twice-weekly schedule as Vagifem. Note: systemic absorption may differ slightly.
• Estring (estradiol 2 mg ring / 7.5 mcg/day, Pfizer): Continuous low-dose estradiol release over 90 days. Check current availability before prescribing (shortage in 2024).
• Estradiol vaginal cream (Estrace or generic): Widely available; lower cost. Clinical evidence supports equivalent efficacy to inserts for GSM. Requires patient counseling on application.

Tier 3 — Different molecule, same tissue target:

• Premarin Vaginal Cream (conjugated estrogens): Clinically equivalent to estradiol products for GSM symptoms. Brand-only. Good option for patients on Premarin formulary tier.
• Intrarosa (prasterone 6.5 mg vaginal insert, AMAG/Millicent): Daily DHEA vaginal insert. FDA-approved for moderate-to-severe dyspareunia. Locally converts to estrogen and androgens. Option for patients with contraindications to traditional estrogen therapy; discuss with oncology if applicable.
• Osphena (ospemifene 60 mg tablet, Shionogi): Oral SERM. FDA-approved for dyspareunia and vaginal dryness. Agonist at vaginal estrogen receptors, partial antagonist at uterus. Consider for patients with aversion to vaginal administration.

Prescribing Strategy: Enable Generic Substitution

The most practical near-term strategy to help patients avoid availability gaps is to prescribe generically rather than brand-specifically when possible. Writing for "estradiol vaginal inserts 10 mcg — generic substitution permitted" (DAW-0) rather than "Vagifem" ensures your patient has access to any FDA-approved bioequivalent product available at their pharmacy, including Yuvafem, Teva, or Glenmark generics.

Formulary and Insurance Considerations

Coverage for Vagifem and estradiol vaginal inserts varies significantly by plan type. Approximately 76% of commercial insurance plans cover Vagifem, but fewer than 10% of Medicare Part D plans provide coverage. ACA marketplace plans cover it in approximately 63% of cases.

When patients face coverage barriers in addition to availability challenges, consider:

• Formulary exception appeal for patients on Medicare Part D
• The Novo Nordisk Patient Assistance Program (PAP) for uninsured/underinsured patients at ≤400% FPL (phone: 1-866-310-7549)
• GoodRx and SingleCare coupons that may reduce cost to ~$47-$175 for patients paying out of pocket

How medfinder Can Support Your Patients

If your patients are struggling to locate Vagifem at local pharmacies, medfinder is a service that contacts pharmacies on their behalf to find out which ones can fill their prescription. Patients provide their medication, dosage, and ZIP code — medfinder does the calling and texts them the results. This is particularly useful for busy patients or those in areas where pharmacies are sparse.

For a practical framework for helping patients navigate stock availability, see our provider guide to helping patients find Vagifem.